2015-04-15 05:10 PT - News Release 

VP Close 2015-04-14 C$ 0.19
Mr. Otto Folprecht reports


April 15, 2015- Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (CSE: VP /
FSE: 1JV /Q:VDQSF) is pleased to announce it has entered into a lease to own
arrangement for a facility in Bellingham, Washington that will allow Vodis USA to
develop a turnkey solution to future license holders under the I-502 regulation in
Washington State.

Otto Folprecht, CEO and Director of Vodis, states, “We’re thrilled that our new
Bellingham facility can be easily retro-fitted into a state-of-the-art 17,000 square
foot production and processing facility. This is a major milestone in the company's
aspiration of becoming an international brand in the cannabis and pharmaceutical

Vodis USA Inc, a fully owned subsidiary of Vodis Pharmaceuticals Inc, will grant a
license to manufacture, market and sell certain products under the VIP brand.
Through this program Vodis USA LLC will allow licensed Washington State growers
access to its Quality Assurance Program (QAP), Good Manufacturing Practices
(GMP), Generally Accepted Agricultural Practices (GAAP), expertise and production

While Vodis Pharmaceuticals and its subsidiaries cannot have any whatsoever
interest in any proceeds as a result of production, processing or retail activities in
the United States, it can license its brand, production and consulting services to
approved Washington State license holders to ensure that all products produced
under the Vodis Pharmaceuticals program and/or associated under the VIP brand
meet or exceed the Vodis brand quality standards.

About the Washington I-502 marijuana market
In November, 2012, the Washington State Liquor Control Board (WSLCB) passed
Initiative 502 (I-502), pursuant to a vote by the people of the State of Washington. I-
502 authorized the WSLCB to regulate and tax recreational marijuana products for
persons over 21 years of age and thereby created a new industry for the growing,
processing and selling of recreational marijuana products regulated by Washington
State. A recent WSLCB-commissioned report by the Rand organization suggests that
there are currently up to 700,000 recreational marijuana users in Washington State
worth approximately $1.25-billion (U.S.) to $1.5-billion (U.S.) in annual sales.
Also, the company is waiting for final inspection from Health Canada of its Delta BC 
medical marijuana production facility.

For further information please contact:

Richard Schnoor
Head of Corporate Communications
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B5
Direct: 1-866-210-1420 ext. 110
Web: www.vodis.ca

The Canadian Securities Exchange has neither approved nor disapproved the
contents of this news release and accepts no responsibility for the adequacy or
accuracy hereof.
Forward-Looking Information:
This news release contains forward-looking statements, which relate to future events
or future performance and reflect management's current expectations and
assumptions. Such forward-looking statements reflect management's current beliefs
and are based on assumptions made by and information currently available to the
Company. Readers are cautioned that these forward looking statements are neither
promises nor guarantees, and are subject to risks and uncertainties that may cause
future results to differ materially from those expected. All of the forward-looking
statements made in this news release and any accompanying graphic links are
qualified by these cautionary statements and those in our continuous disclosure filings
available on SEDAR at www.sedar.com. These forward-looking statements are made
as of the date hereof and the Company does not assume any obligation to update or
revise them to reflect new events or circumstances save as required under applicable
securities legislation. This news release does not constitute an offer to sell securities
and the Company is not soliciting an offer to buy securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such jurisdiction.

Vodis Corporate

  • Page 1 of 75